RT Journal Article
SR Electronic
T1 LITE SABR M1: a phase I trial of Lattice SBRT for large tumors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.05.21257825
DO 10.1101/2021.06.05.21257825
A1 Sai Duriseti
A1 James Kavanaugh
A1 Jeff Szymanski
A1 Yi Huang
A1 Franco Basarabescu
A1 Lauren Henke
A1 Pamela Samson
A1 Alexander Lin
A1 Aadel Chaudhuri
A1 Clifford Robinson
A1 Matthew B Spraker
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2021.06.05.21257825.abstract
AB Purpose Stereotactic body radiotherapy (SBRT) is an attractive treatment option for patients with metastatic and/or unresectable tumors, however its use is limited to smaller tumors. Lattice is a form of spatially fractionated radiotherapy that may offer safe delivery of SBRT for bulky tumors. We previously described Lattice SBRT, which delivers 20 Gy in 5 fractions with a simultaneous Lattice boost to 66.7 Gy. The goal of this study was to prospectively evaluate the acute toxicity and quality of life (QoL) of patients with large tumors (> 5 cm) treated with Lattice SBRT.Methods This was a single-arm phase I trial conducted between October 2019 and August 2020. Patients with tumors >4.5 cm were eligible. Lattice SBRT was delivered every other day then patients were evaluated for 90 days. The primary outcome was the rate of treatment-associated grade 3+ acute toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Other outcomes included patient reported toxicity and QoL inventories, and GTV changes following Lattice SBRT.Results Twenty patients (22 tumors) were enrolled. Median gross tumor volume (GTV) was 783 cc (range: 64-3713 cc). Fifty percent of tumors were in the thorax, 45% abdomen/pelvis, and 5% extremity. There was no grade 3+ toxicity probably or definitely attributable to Lattice SBRT. There was one case of grade 4 toxicity possibly associated with Lattice SBRT.Conclusions This phase I study met its primary endpoint of physician reported safety, confirmed with secondary PRO-CTCAE outcomes. Early efficacy, as demonstrated by PROMIS QoL and imaging, is encouraging. An ongoing phase II clinical trial of Lattice SBRT is evaluating the safety and efficacy of this novel technique.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04133415Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was a prospective, single-arm, single-institution phase 1 trial approved by the Siteman Cancer Center Protocol Review and Monitoring Committee and the Human Research Protection Office at Washington University in St. Louis. All eligible patients provided signed consent for voluntary participation in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are stored locally, please contact the corresponding author to discuss.